It is questionable whether primary Posaconazole prophylaxis would have been able to prevent the Aspergillus infection, allowing for timely
consolidation chemotherapy. However, it is known that Posaconazole prophylaxis reduces the incidence of invasive fungal disease from 8% to 2% in high risk AML and myelodysplastic syndrome patients [9-11].
Different practitioners or institutions have varied standards of protocols, with induction chemotherapy before concurrent chemo-RT preferred by some,[sup][4] and others practicing
consolidation chemotherapy after concurrent chemo-RT.[sup][5] As far as recommended systemic treatment for stage 3 NSCLC is concerned, it comprises 2–4 cycles of chemotherapy.
Background: The postremission therapies for adult patients generally contain
consolidation chemotherapy, allogeneic hematopoietic stem cell transplantation and autologous hematopoietic stem cell transplantation (auto-HSCT).
All patients had received prior therapy consisting of induction combination chemotherapy, maximum feasible surgical resection, myeloablative
consolidation chemotherapy followed by autologous stem cell transplant and radiation therapy to residual soft tissue disease, concluded the company.
The patient is currently in remission and is being monitored in the course of allogeneic hematopoietic stem cell transplantation to follow
consolidation chemotherapy.
After induction, patients could receive up to four cycles of
consolidation chemotherapy while continuing ivosidenib or enasidenib.
She remained in mCR while receiving
consolidation chemotherapy. She ultimately relapsed after 18 months of treatment while on oral maintenance and survived on secondary chemotherapy regimens without achieving durable mCR.